ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Zacks12-16

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492961989?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326","is_english":true,"pubTime":"2024-12-16 22:42","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492961989","market":"us","top_or_hot":-1,"title":"ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline","media":"Zacks","content":"<div>\n<p>AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 22:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0738911758.USD","symbol_name":"Blackrock Global Equity Income A6 USD","start_time":0,"source_url":"https://finance.yahoo.com/news/abbv-acquire-nimble-therapeutics-strengthen-144200195.html","article_id":"2492961989","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/D3ML88PGy1H5kHT9yl7OAw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492961989","pubTimestamp":1734360120,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AbbVieABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.Nimble’s lead preclinical asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and inflammatory bowel disease . Per AbbVie, IL23R is a validated therapeutic target in certain autoimmune diseases, significantly contributing to psoriasis and IBD by driving inflammation and enhancing immune responses.In the past three months, shares of AbbVie have lost 10.4% compared with the industry’s 14.4% decline.Skyrizi and Rinvoq are expected to collecti","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0738911758.USD":"Blackrock Global Equity Income A6 USD","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SPRO":"Spero Therapeutics Inc.","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0882574055.USD":"富达全球健康医疗A ACC","ABBV":"艾伯维公司","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","CSTL":"Castle Biosciences, Inc.","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4566":"资本集团","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4196":"保健护理服务","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LENZ":"Therapeutics","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IBD":"Inspire Corporate Bond ETF","BK4588":"碎股","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","CTMX":"CytomX","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS"},"translate_title":"ABBV将收购Nimble Therapeutics以加强免疫学产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":1,"CSTL":1,"CTMX":1,"IBD":1,"ABBV":1,"LENZ":1},"content_text":"AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases to AbbiVie’s Immunology pipeline. The acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics.\nNimble’s lead preclinical asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and inflammatory bowel disease (IBD). Per AbbVie, IL23R is a validated therapeutic target in certain autoimmune diseases, significantly contributing to psoriasis and IBD by driving inflammation and enhancing immune responses.\nIn the past three months, shares of AbbVie have lost 10.4% compared with the industry’s 14.4% decline. \nImage Source: Zacks Investment Research\nMore on ABBV’s Strategic Acquisition of Nimble\nThe acquisition of Nimble Therapeutics by AbbVie is poised to benefit both. AbbVie will gain a valuable addition to its pipeline, enhancing its established expertise in immunology with Nimble's innovative oral peptide-based therapies. This synergy represents a significant growth opportunity to address unmet medical needs in autoimmune diseases.\nFor Nimble, AbbVie’s global scale and proven capabilities in developing and commercializing medicines will enable its groundbreaking therapies to reach a wider patient population. The collaboration underscores the potential of Nimble’s proprietary platform.\nUnder the terms of the acquisition agreement, AbbVie will make a cash payment of $200 million to Nimble, subject to the fulfillment of certain customary closing conditions. ABBV has also made certain interim funding payments to Nimble before the transaction closes and remains liable to pay an additional amount contingent upon the achievement of a developmental milestone.\nAbbVie Holds Key Position in Immunology Market\nAbbVie enjoys a strong foothold in the Immunology market. AbbVie’s key immunology medicine,Humira, is facing generic erosion due to the loss of patent protection in the United States and EU. However, sales of its two new drugs, Skyrizi and Rinvoq, approved across Humira's major indications, plus a distinct new indication, atopic dermatitis, are making up for the loss.\nThe drugs have demonstrated a strong uptake, contributing meaningful revenues that are boosting the company’s top line. In the first nine months of 2024, AbbVie has recorded $12 billion from the sales of Skyrizi and Rinvoq. Both drugs have demonstrated compelling head-to-head data against several novel therapies in clinical studies, giving them a competitive advantage. With approvals for many new indications, sales of these drugs could be higher in future quarters.\nSkyrizi and Rinvoq are expected to collectively exceed the peak revenues achieved by Humira by 2027. AbbVie expects combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion by 2027 (Skyrizi: more than $17 billion; Rinvoq: more than $10 billion).\n\nAbbVie Inc. Price and Consensus\n\nAbbVie Inc. price-consensus-chart | AbbVie Inc. Quote\n\nABBV’s Zacks Rank and Stocks to Consider\nAbbVie currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 58 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.84. In the past three months, shares of Castle Biosciences have lost 7.6%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 8.3%.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 19.5%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAbbVie Inc. (ABBV) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492961989"}